| Status: AWMSG assessment in progress | |
For the off-label maintenance treatment of acute myeloid leukaemia (AML) in patients with FLT3 mutation and evidence of minimum residual disease, before or after haematopoietic stem cell transplant. The AWMSG Scrutiny Panel considered gilteritinib suitable for a One Wales assessment for off-label medicines at their meeting on 05/02/2026. |
|
Medicine details |
|
| Medicine name | gilteritinib (Gilteritinib Astellas®) |
| Formulation | 40 mg film-coated tablet |
| Reference number | OW36 |
| Indication | As above |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | One Wales |
| Status | AWMSG assessment in progress |
| Scrutiny Panel meeting date | 05/02/2026 |
| OWMAG meeting date | TBC |
| AWMSG meeting date | TBC |
| Further information The AWMSG Scrutiny Panel considered gilteritinib suitable for a One Wales assessment for off-label medicines at their meeting on 05/02/2026. |
|